Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -45

Boston Scientific (BSX) Stock Falls After Cyberattack Wipes Out Earnings Guidance

AI-generated analysis

πŸ“‰ Boston Scientific stock dropped 2.3% to $46.68 after formally warning it will likely miss Q3 and full-year 2026 earnings and sales guidance due to a cyberattack.

🚫 The company shifted from previously stating the financial impact was undetermined to explicitly saying it is 'unlikely to meet' its net sales growth and adjusted EPS targets.

πŸ’° Previous guidance included full-year sales growth of 5.5% to 6.5% and adjusted EPS between $3.28 and $3.32, which are now expected to be missed.

πŸ“Š Wall Street consensus for full-year adjusted EPS was $3.30 on net sales of $21.35 billion, with Q3 EPS expectations at 81 cents.

πŸ“‰ The stock has underperformed significantly, falling 50% year-to-date and 55% over the past 12 months while trading near its 52-week low.

πŸ” Analysts Argus Research, Baird, JPMorgan, and Bank of America have downgraded or trimmed price targets citing growth concerns and cyberattack impacts.

🏭 Major distribution centers were processing and shipping products at normal levels as of September 5, though this did not offset the guidance miss.

πŸ”’ Boston Scientific reported no evidence of ongoing unauthorized access but confirmed the investigation remains active.

πŸ“… The company will provide a comprehensive update on operational and financial outlooks regarding the cyberattack during its Q3 earnings call on October 28.

πŸ₯ Medtech peers Abbott and Medtronic have also faced cybersecurity incidents in 2026, adding broader sector pressure to Boston Scientific's situation.

Bullish Signals
  • Boston Scientific stated it has not found evidence of ongoing unauthorized access to its systems following the cyberattack.
  • The company expects to recover some portion of lost revenue as operations ramp back up, customer orders are fulfilled, and backlogs are reduced.
  • Major distribution centers were processing and shipping products at or above normal levels as of September 5.
Risk Factors
  • Boston Scientific formally warned it is unlikely to meet its net sales growth and adjusted EPS guidance for Q3 and full-year 2026 due to a cyberattack.
  • The company's stance hardened from previously stating the financial impact was undetermined to explicitly forecasting a miss on earnings and sales targets.
  • Analysts Argus Research, Baird, JPMorgan, and Bank of America have downgraded or trimmed price targets citing growth concerns and cyberattack impacts.
  • The stock has fallen 50% year-to-date and 55% over the past 12 months, trading far below its 52-week high of $109.50.
  • Medtech peers Abbott and Medtronic have also dealt with cybersecurity incidents in 2026, keeping broader sector sentiment under pressure.
Full Analysis
Boston Scientific (BSX) stock fell 2.3% in premarket trading after the company formally warned it is unlikely to meet its net sales growth and adjusted EPS guidance for both Q3 and full-year 2026. This revised stance follows a cyberattack disclosed on August 25, which has forced management to abandon previous forecasts of 5.5% to 6.5% full-year sales growth and $3.28 to $3.32 adjusted EPS. The company previously indicated the financial impact of the breach was undetermined, but Tuesday's regulatory filing marked a significant deterioration in outlook. Wall Street analysts had expected full-year adjusted EPS of $3.30 on net sales of $21.35 billion, while Q3 consensus estimates were set at 81 cents EPS and $5.26 billion in sales. Despite the negative guidance update, Boston Scientific stated it has not found evidence of ongoing unauthorized access and expects to recover some lost revenue as operations ramp back up. The company plans to provide a full update on its operational and financial outlook, including the specific impact of the cyberattack, during its Q3 earnings call scheduled for October 28.